anacetrapib Articles
EMA starts review of Merck & Co's cholesterol drug Tredaptive
24 December 2012
Discontinuation of dalcetrapib leaves Merck's anacetrapib as the front-running novel CETP inhibitor for dyslipidemia
20 September 2012
Merck & Co to file for approval of two heart drugs next year
28 August 2012
US genericization of clopidogrel will initially contract ACS market, before uptake of novel oral agents lifts sector to $2.7 billion
27 August 2012
Merck & Co's Ph III cholesterol inhibitor anacetrapib meets safety and efficacy endpoints in patients with CHD
18 November 2010
Showing 1-5 of 5 articles
- 1
- Encouraging results with Sangamo's SB-728-T in HIV treatment
- Bristol-Myers' data on Yervoy and nivolumab causes a stir
- AstraZeneca plans to move three cancer drug candidates into Ph III
- Sanofi prepares for regulatory filing of MF candidate on positive JAKARTA study results
- Merck Serono Ph III trial of L-BLP25 fails endpoint in NSCLC
